Cordis and Boston Scientific: Advancements in Coronary and Peripheral Artery Disease Treatment

Cordis enrolls the first patient in SELUTION4DeNovo IDE trial, a coronary de novo study for SELUTION SLR Drug-Eluting Balloon (DEB), while Boston Scientific reports positive results from its drug-coated balloon in treating patients with repeat blockages. Cordis completes patient enrollment in SELUTION SLR SUCCESS PTA Study, a large post-market study evaluating the safety, efficacy, health economics, and patient-reported quality-of-life data of the SELUTION SLR Drug-Eluting Balloon (DEB) in treating peripheral artery disease (PAD). Cordis acquires Swiss-based MedAlliance, adding MedAlliances sustained sirolimus drug-eluting balloon to its product line.